Ensysce Biosciences posts investor presentation spotlighting trypsin-controlled opioid platforms, pain pipeline
ENSC•Investor presentation highlights TAAP and MPAR opioid platforms
Ensysce Biosciences highlighted its TAAP and MPAR platforms aimed at opioids with abuse deterrence and oral overdose protection using trypsin-controlled drug release.
PF614-MPAR development plan targets Phase 1b SAD continuation in 2026, a Phase 3 efficacy-safety study in 2026, and NDA filing in 2028.
The company cited Breakthrough Therapy designation for a TAAP oxycodone combination product, granted by the FDA in January 2024.
Its Cy Biopharma unit outlined CY200/201 for complex regional pain syndrome, citing FDA orphan drug designation in 2026.
Preclinical and early clinical summaries described overdose-related suppression of oxycodone release with nafamostat, while maintaining release at prescribed doses.
